Dr. Kuter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Yaw 7b Hematology Oncology
Boston, MA 02114Phone+1 617-724-6193Fax+1 617-643-1915- Is this information wrong?
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 1978 - 1983
Harvard Medical SchoolClass of 1978
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology
Certifications & Licensure
MA State Medical License 1987 - 2025
ME State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures Start of enrollment: 2006 Mar 01
- Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study) Start of enrollment: 2008 Jan 01
- Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.David J Kuter, Jiri Mayer, Merlin Efraim, Lachezar H Bogdanov, Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Y Choi, A J Gerard Jansen, Vickie McDonald, Ro...> ;Blood Advances. 2024 Apr 9
- 1 citationsCorrection to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.Alexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, Jun Su, Xiaoyu Jiang, William Hobbs, Jaime Morales, Frank Shafer, David J Kuter, Ilene...> ;Annals of Hematology. 2024 May 1
- How I treat thrombocytopenia in pregnancy.Annemarie E Fogerty, David J Kuter> ;Blood. 2024 Feb 29
- Join now to see all
Journal Articles
- Romiplostim in Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia (ITP) for up to 1 Year and in Those with Chronic ITP for More Than 1 Year: A S...David J Kuter, Bhakti Mehta, British Journal of Haematology
- Presenting Signs and Patient Co‐Variables in Gaucher Disease: Outcome of the Gaucher Early Diagnosis Consensus (GED‐C) Delphi InitiativeDavid J Kuter, Neal J Weinreb, Internal Medicine Journal
Abstracts/Posters
- Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune ThrombocytopeniaDavid J. Kuter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesAmerican Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies2013 International Conference, Philadelphia, Pennsylvania, USA
- Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Other
- Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2012-07-24 - Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2013-01-30 - Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesDavid Kuter, MD, British Journal of Haematology
https://www.doximity.com/articles/d909d298-5043-4c91-b3f6-84a999dd1fef
UpToDate, Wolters Kluwer Health - 2012-09-07
Press Mentions
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and ExpositionNovember 3rd, 2022- Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialJune 12th, 2020
New Trial Explores Two Sides of Deep Vein Thrombosis TreatmentFebruary 14th, 2011- Join now to see all
Grant Support
- MGH Transfusion Medicine And Hemostasis Network Clinical Core CenterNational Heart, Lung, And Blood Institute2009
- A Proteogenomic Analysis Of Platelets In Patients With Essential ThrombocythemiaNational Heart, Lung, And Blood Institute2007–2008
- A Proteogenomic Analysis Of Platelets In Patients With *National Heart, Lung, And Blood Institute2006
- Studies Of Rhutpo In ITP And Of Rvlla In Liver DiseaseNational Heart, Lung, And Blood Institute2002–2006
- Proteogenomic Analysis Of Platelets In ThrombocythemiaNational Heart, Lung, And Blood Institute2005
- Molecular And Cellular Mechanisms Of Platelet ViabilityNational Heart, Lung, And Blood Institute1998–2001
- Molecular Physiology Of ThrombopoietinNational Heart, Lung, And Blood Institute1995–1999
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
